Oppenheimer & Co. Inc. lifted its holdings in shares of Thermo Fisher Scientific Inc (NYSE:TMO) by 12.4% in the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 84,483 shares of the medical research company’s stock after purchasing an additional 9,290 shares during the quarter. Oppenheimer & Co. Inc.’s holdings in Thermo Fisher Scientific were worth $14,740,000 at the end of the most recent quarter.
Several other hedge funds and other institutional investors have also modified their holdings of TMO. BlackRock Inc. grew its holdings in shares of Thermo Fisher Scientific by 2,692.1% during the first quarter. BlackRock Inc. now owns 22,988,885 shares of the medical research company’s stock worth $3,531,095,000 after purchasing an additional 22,165,530 shares in the last quarter. Veritas Asset Management LLP grew its holdings in shares of Thermo Fisher Scientific by 112.4% during the second quarter. Veritas Asset Management LLP now owns 2,430,759 shares of the medical research company’s stock worth $424,095,000 after purchasing an additional 1,286,259 shares in the last quarter. Harbour Capital Advisors LLC grew its holdings in shares of Thermo Fisher Scientific by 18,197.5% during the second quarter. Harbour Capital Advisors LLC now owns 1,201,051 shares of the medical research company’s stock worth $6,884,000 after purchasing an additional 1,194,487 shares in the last quarter. Vanguard Group Inc. grew its holdings in shares of Thermo Fisher Scientific by 2.7% during the first quarter. Vanguard Group Inc. now owns 25,971,301 shares of the medical research company’s stock worth $3,989,193,000 after purchasing an additional 695,079 shares in the last quarter. Finally, Renaissance Technologies LLC grew its holdings in shares of Thermo Fisher Scientific by 68.8% during the first quarter. Renaissance Technologies LLC now owns 1,373,044 shares of the medical research company’s stock worth $210,900,000 after purchasing an additional 559,400 shares in the last quarter. 83.36% of the stock is owned by institutional investors.
COPYRIGHT VIOLATION WARNING: “Thermo Fisher Scientific Inc (TMO) Stake Lifted by Oppenheimer & Co. Inc.” was originally published by BBNS and is the property of of BBNS. If you are viewing this piece of content on another website, it was copied illegally and republished in violation of international copyright & trademark legislation. The original version of this piece of content can be accessed at https://baseballnewssource.com/markets/thermo-fisher-scientific-inc-tmo-stake-lifted-by-oppenheimer-co-inc/1700938.html.
In other Thermo Fisher Scientific news, VP Peter E. Hornstra sold 3,894 shares of the firm’s stock in a transaction that occurred on Tuesday, September 5th. The stock was sold at an average price of $185.18, for a total transaction of $721,090.92. Following the completion of the transaction, the vice president now owns 19,751 shares in the company, valued at approximately $3,657,490.18. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, Director Jim P. Manzi sold 1,000 shares of the firm’s stock in a transaction that occurred on Thursday, August 17th. The shares were sold at an average price of $175.20, for a total value of $175,200.00. Following the transaction, the director now owns 38,757 shares of the company’s stock, valued at approximately $6,790,226.40. The disclosure for this sale can be found here. Insiders have sold a total of 52,738 shares of company stock valued at $9,302,112 in the last 90 days. 0.49% of the stock is currently owned by company insiders.
Shares of Thermo Fisher Scientific Inc (TMO) opened at 193.21 on Monday. The firm has a 50-day moving average price of $186.68 and a 200 day moving average price of $173.88. Thermo Fisher Scientific Inc has a 52 week low of $139.07 and a 52 week high of $194.30. The stock has a market cap of $75.37 billion, a price-to-earnings ratio of 33.66 and a beta of 1.05.
Thermo Fisher Scientific (NYSE:TMO) last released its quarterly earnings results on Wednesday, July 26th. The medical research company reported $2.30 earnings per share for the quarter, beating the consensus estimate of $2.27 by $0.03. The business had revenue of $5 billion during the quarter, compared to analysts’ expectations of $4.92 billion. Thermo Fisher Scientific had a return on equity of 15.97% and a net margin of 11.80%. The firm’s revenue for the quarter was up 10.2% compared to the same quarter last year. During the same quarter last year, the business posted $2.03 EPS. On average, analysts forecast that Thermo Fisher Scientific Inc will post $9.35 EPS for the current fiscal year.
The company also recently declared a quarterly dividend, which will be paid on Monday, October 16th. Shareholders of record on Friday, September 15th will be issued a dividend of $0.15 per share. This represents a $0.60 annualized dividend and a yield of 0.31%. The ex-dividend date is Thursday, September 14th. Thermo Fisher Scientific’s dividend payout ratio is presently 10.45%.
Several brokerages have recently commented on TMO. Zacks Investment Research lowered Thermo Fisher Scientific from a “buy” rating to a “hold” rating in a report on Tuesday, September 12th. Cowen and Company reissued an “outperform” rating and set a $220.00 price objective (up previously from $200.00) on shares of Thermo Fisher Scientific in a report on Sunday, September 10th. Barclays PLC reaffirmed an “overweight” rating and issued a $215.00 target price (up previously from $200.00) on shares of Thermo Fisher Scientific in a research note on Monday, September 25th. Goldman Sachs Group, Inc. (The) started coverage on Thermo Fisher Scientific in a research note on Tuesday, September 26th. They issued a “buy” rating and a $225.00 target price for the company. Finally, Jefferies Group LLC reaffirmed a “hold” rating and issued a $195.00 target price on shares of Thermo Fisher Scientific in a research note on Thursday, September 28th. One research analyst has rated the stock with a hold rating and sixteen have given a buy rating to the company. The company currently has a consensus rating of “Buy” and an average target price of $202.21.
Thermo Fisher Scientific Company Profile
Thermo Fisher Scientific Inc develops, manufactures and sells a range of products. The Company provides analytical instruments, equipment, reagents and consumables, software and services for research, manufacturing, analysis, discovery and diagnostics. It operates through four segments: Life Sciences Solutions, Analytical Instruments, Specialty Diagnostics, and Laboratory Products and Services.
Want to see what other hedge funds are holding TMO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Thermo Fisher Scientific Inc (NYSE:TMO).
Receive News & Ratings for Thermo Fisher Scientific Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Thermo Fisher Scientific Inc and related companies with our FREE daily email newsletter.